Back to discover
Drug

Aluminum

In clinical development
Emerging researchLate-stage development
Also known as Al, Aluminium atom, Aluminium element, Aluminium metallicum+6 more

Al, Aluminium atom, Aluminium element, Aluminium metallicum, Aluminum element, Aluminum metal, CI 77000, Metallic aluminum, Aluminio, Aluminium.

RxNorm1311504UNIICPD4NFA903
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Aluminum phosphate-modified red clay as a stable nanocomposite catalyst for the selective conversion of methanol to dimethyl ether

Industry2026-08-04Nature — Environmental Sciences

DFT insights into indole detection and removal using aluminum and zinc doped coronene

Industry2026-07-23Nature — Environmental Sciences

Monitoring the Therapeutic Efficacy of the Combinations Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 5 Years of Age in Five Sentinel Sites in Mozambique

Clinical trial2025-07-30Completed · ClinicalTrials.gov

HPV vaccines induce trained immunity and modulate pro-inflammatory cytokine expression in response to secondary Toll-like receptor stimulations.

Research2023-12-17Microbiology and immunology

Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria

Clinical trial2009-10-01Primary completion · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Aluminum
Aliases & brands
AlAluminium atomAluminium elementAluminium metallicumAluminum elementAluminum metalCI 77000Metallic aluminumAluminioAluminium
RxNorm CUI
1311504
UNII
CPD4NFA903

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
LATEST COMPLETION 2025
2
Late-stage (III+)
1
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 2
Phase 42

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Papillomavirus Infections1Papillomavirus Vaccines1
Journals, researchers & institutions
Top journals
  • Microbiology and immunology1
Leading researchers
  • Fukushima Y1
  • Kouwaki T1
  • Mtali YS1
  • Oshiumi H1
  • Sonokawa H1
  • Takashima K1
  • Yamaguchi M1
Leading institutions
free-text, unnormalised
  • Graduate School of Medical Sciences1
  • School of Medicine1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials